ARVINAS, INC. Income (Loss) from Equity Method Investments
ARVINAS, INC. (ARVN) reported Income (Loss) from Equity Method Investments of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-02-24
- ARVINAS, INC. income (loss) from equity method investments for the quarter ending 2024-12-31 was $0.00.
- ARVINAS, INC. income (loss) from equity method investments for the quarter ending 2024-09-30 was $0.00.
- ARVINAS, INC. income (loss) from equity method investments for the quarter ending 2024-06-30 was $0.00.
- ARVINAS, INC. income (loss) from equity method investments for the quarter ending 2024-03-31 was $0.00.
- ARVINAS, INC. income (loss) from equity method investments for fiscal 2025 was $0.00.
- ARVINAS, INC. income (loss) from equity method investments for fiscal 2024 was $0.00.
- ARVINAS, INC. income (loss) from equity method investments for fiscal 2023 was -$2.50M.
- ARVINAS, INC. income (loss) from equity method investments for fiscal 2022 was -$10.60M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month | Income (Loss) from Equity Method Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-24 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-10-30 | $0.00 derived: sum of 2 quarters · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-07-30 | $0.00 10-Q · filed 2024-07-30 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | -$100.00K derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | -$100.00K derived: sum of 3 quarters · filed 2026-02-24 | -$1.40M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$100.00K derived: sum of 2 quarters · filed 2026-02-24 | -$1.40M derived: sum of 3 quarters · filed 2026-02-24 | -$2.50M 10-K · filed 2026-02-24 | |
| 2023-09-30 | -$100.00K 10-Q · filed 2024-10-30 | -$1.40M derived: sum of 2 quarters · filed 2024-10-30 | -$2.50M 10-Q · filed 2024-10-30 | -$5.30M derived: sum of 4 quarters · filed 2025-02-11 | |
| 2023-06-30 | -$1.30M 10-Q · filed 2024-07-30 | -$2.40M 10-Q · filed 2024-07-30 | -$5.20M derived: sum of 3 quarters · filed 2025-02-11 | -$8.10M derived: sum of 4 quarters · filed 2025-02-11 | |
| 2023-03-31 | -$1.10M 10-Q · filed 2024-05-07 | -$3.90M derived: sum of 2 quarters · filed 2025-02-11 | -$6.80M derived: sum of 3 quarters · filed 2025-02-11 | -$9.30M derived: sum of 4 quarters · filed 2025-02-11 | |
| 2022-12-31 | -$2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | -$5.70M derived: sum of 2 quarters · filed 2025-02-11 | -$8.20M derived: sum of 3 quarters · filed 2025-02-11 | -$10.60M 10-K · filed 2025-02-11 | |
| 2022-09-30 | -$2.90M 10-Q · filed 2023-11-07 | -$5.40M derived: sum of 2 quarters · filed 2023-11-07 | -$7.80M 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | -$2.50M 10-Q · filed 2023-08-08 | -$4.80M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | -$2.30M 10-Q · filed 2023-05-05 | ||||
| 2021-12-31 | -$6.90M 10-K · filed 2024-02-27 | $0.00 10-K · filed 2022-02-28 | |||
| 2020-12-31 | -$4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$4.10M derived: sum of 2 quarters · filed 2023-02-23 | -$4.10M 10-K · filed 2023-02-23 | $0.00 10-K · filed 2021-03-01 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |||
| 2019-12-31 | -$25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$24.70M derived: sum of 2 quarters · filed 2022-02-28 | -$24.70M 10-K · filed 2022-02-28 | -$24.68M 10-K · filed 2020-03-16 | |
| 2019-09-30 | -$24.68M 10-Q · filed 2020-11-05 | -$24.68M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-04 | $0.00 10-Q · filed 2019-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |